Oncolytics doses first subject in pancreatic cancer trial

Oncolytics Biotech has dosed the first patient with a combination therapy of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) for metastatic pancreatic cancer as part of the Gastrointestinal tumOrs trials.